WuXi Bio's business update has completely caused investors to lose confidence. There're doubts about whether future performance guidance can be achieved. It's time to consider the worst-case scenario.
Boomeranged on Tue, 12 Dec 2023 09:47
Even though WuXi Bio launches US$600 million share repurchase, share price doesn't stop falling.Obviously, recent business update has changed investors' expectations/confidence of the outlook.It also remains to be seen whether future performance will recover as expected. After the spin-off of WuXi XDC, WuXi Bio becomes increasingly unattractive. In extreme case, over 2x P/B ratio is not impossible
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.